Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712 is a research paper published in Pediatric Blood & Cancer (2023). On theSindex it has a DataRank of 0.208. It has been cited 3 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: UM1CA228823
National Institute of General Medical Sciences
Grant: T32GM 08685
NCI NIH HHS
Grant: R01 CA164024
NIGMS NIH HHS
Grant: T32 GM008685
NCI NIH HHS
Grant: P30 CA015083
FWCI
0.37
Citation Percentile
0.5%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals